Definitive Contract 75A50119C00007

This is a federal contract award made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS), to Venatorx Pharmaceuticals Inc., a biopharmaceutical company specializing in the discovery and development of novel anti-infective therapeutics. The contract, valued at $147,481,537.00, does not have a set-aside designation and was awarded as a definitive, cost-sharing contract. The work under this contract focuses on the advanced research and development of medical countermeasures against chemical, biological, radiological, nuclear, and pandemic influenza threats, which aligns with ASPR's mission to support the preparedness and response capabilities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). Key projects include the development of new antibiotics, antivirals, and treatments for biothreat pathogens. This contract was awarded under a Broad Agency Announcement (BAA) solicitation from BARDA, which sought proposals for a range of medical countermeasure research and development activities.